###### Strengths and limitations of this study

-   This is the first comprehensive literature review and network meta-analysis (NMA) summarising the available clinical trial literature on the clinical benefits of the newly approved basal insulin, Gla-300, and potential basal insulin comparators, and enabling comparisons between these therapies.

-   The systematic literature review was limited to only English language literature; while this is likely to include all major randomised clinical trials conducted for basal insulin therapy in type 2 diabetes mellitus (T2DM), it may exclude smaller studies with no publication in English.

-   The NMA was conducted in accordance with National Institute for Health and Care Excellence guidance and extensive sensitivity analyses were utilised to assess the robustness of the findings.

-   While NMA enables the synthesis of available clinical information, it is not a substitute for head-to-head clinical trials to compare therapies, and such trials should be encouraged and conducted.

Introduction {#s1}
============

Worldwide, approximately 348.3 million people are living with type 2 diabetes mellitus (T2DM).[@R1] [@R2] As T2DM progresses, insulin therapy may be required to achieve glycaemic control. The 2015 ADA/EASD Position Statement on Managing Hyperglycemia in T2DM recommends initiating basal insulin in combination with oral therapy among the appropriate options for patients who are unable to achieve their glycated haemoglobin (HbA1c) target after 3 months of metformin monotherapy.[@R3]

Insulin glargine 300 u/mL (Gla-300) is a new basal insulin that has recently (2015) been approved by the European Commission and the US Food and Drug Administration. Gla-300 is a concentrated formulation of insulin glargine 100 u/mL (Gla-100), developed to produce a more flat and more prolonged pharmacokinetic and pharmacodynamic profile.[@R4] Several randomised controlled clinical safety and efficacy trials comparing Gla-300 to Gla-100 have shown that Gla-300 achieves reduction in HbA1c comparable to that of Gla-100, while lowering the risk of hypoglycaemia.[@R6] Comparable HbA1c reduction is expected given that each treatment group utilised the same dose titration to achieve fasting plasma glucose of 4.4--5.6 mmol/L (ie, treat-to-target approach). The lower hypoglycaemia rates observed with Gla-300 may be due to properties inherent to the glargine molecule that lead to pharmacokinetic and pharmacodynamic differences at varying concentrations (ie, between Gla-300 and Gla-100).[@R4] [@R5]

At the present time, head-to-head studies of Gla-300 with other available basal insulin options have not been conducted; however, such comparisons would help determine the place in therapy for this product. Meta-analysis enables the findings from multiple primary studies with comparable outcome measures to be combined.[@R9] In absence of direct head-to-head clinical trials, mixed treatment meta-analysis (also known as network meta-analysis (NMA)) may be used to estimate comparative effects of multiple interventions using indirect evidence.[@R9] The current report is an NMA conducted to indirectly compare the efficacy and safety of U300 versus available intermediate-acting to ultra-long-acting basal insulin formulations in the treatment of T2DM.

Methods {#s2}
=======

Systematic literature review {#s2a}
----------------------------

A systematic literature review was conducted to identify evidence for the clinical efficacy and safety of insulin regimens in T2DM according to National Institute for Health and Care Excellence (NICE) standards.[@R9] The following electronic databases were searched: the Cochrane Library (eg, the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effectiveness (DARE)), MEDLINE and MEDLINE In-Process (using Ovid platform), EMBASE (using Ovid Platform) and PsycINFO. Congresses searched were the European Association for the Study of Diabetes (EASD; 2011--2013), the American Diabetes Association (ADA; 2011--2013) and the International Diabetes Federation (IDF; 2011 and 2013). Key search terms included: 'diabetes mellitus, type 2/', 'glargine', 'detemir', 'degludec', 'NPH', 'neutral protamine hagedorn', 'biphasic', 'aspart protamine', 'novomix' and 'premix'. Searches were limited to human, English-language only articles published from 1980 onwards. The NMA focused on studies published recently (ie, based on availability of basal insulin analogues). At the time of analysis, the Gla-300 vs Gla-100 studies were only available in clinical study reports; however, these studies have subsequently been published.[@R6]

Several quality control procedures were in place to ensure appropriate study selection and data extraction. Screening of abstracts and full-text was conducted by two independent researchers (a third independent researcher made a final determination for articles for which there was uncertainty). Data extraction was also conducted by two independent researchers (with reconciliation of discrepancies). Where available, full-text versions of the article were used for data extraction (an abstract or poster was not used unless it was the terminal source document). All processes were documented by the researchers and the data extraction file was also quality checked. The source materials (abstracts, full-text articles) and data extraction files were sorted, and saved on a secure server.

### Inclusion criteria {#s2a1}

In order to be considered for the NMA, clinical studies identified by the systematic literature review had to meet the following criteria: randomised active comparator-controlled clinical studies, patient population of adults with T2DM treated with basal insulin (with or without bolus), patients could be newly initiating insulin (naïve) or already exposed to insulin, and a minimum follow-up of 20 weeks. In addition, studies were required to have patients from at least one of the following countries: the USA, France, Germany, the UK, Spain and/or Italy.

Outcome measures {#s2b}
----------------

Outcome measures analysed by NMA included change in HbA1c (%) from baseline, change in body weight (kg) from baseline and rates of hypoglycaemic events (documented symptomatic and/or nocturnal) per patient year. A documented symptomatic event was defined as an event during which typical symptoms of hypoglycaemia were accompanied by measured plasma glucose under a threshold value. In the EDITION trials, the results were reported using both a concentration of ≤3.0 mmol/L and of ≤3.9 mmol/L. No restriction on the threshold levels was imposed. A 3.9 mmol/L threshold for the EDITION trials was selected to be consistent with the majority of other trials in the network. Nocturnal hypoglycaemic events were defined as any event (confirmed and/or symptomatic) occurring during a period at night.

Statistical methods {#s2c}
-------------------

All analyses were implemented using the statistical software R and OpenBUGS, specifically the packages using Markov Chain Monte Carlo (MCMC). Examples of coding used are provided in an online [supplemental appendix](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2015-009421/-/DC1). Randomised clinical trials that were identified from a systematic literature review and that met the study selection inclusion criteria were analysed using a random-effect Bayesian NMA, following the UK NICE guidance.[@R9] Each outcome was analysed within the evidence network where it was reported. MCMC was used to estimate the posterior distribution for treatment comparison. Continuous outcomes (eg, change in HbA1c or body weight) were modelled assuming a normal likelihood and an identity link. Event rate data (eg, number of hypoglycaemic episodes per patient-year follow-up) were modelled using a Poisson mixed likelihood and log link. Non-informative priors were assumed.

Sensitivity analyses {#s2d}
--------------------

Sensitivity analyses including meta-regression were conducted to evaluate the robustness of the findings. The base scenario included studies of patients on basal insulin-supported oral therapy (BOT; patients received basal insulin in combination with oral antihyperglycaemic drugs but with no bolus insulin; patients could be either---insulin naïve or insulin experienced). Additional scenarios were all studies (ie, patients receiving basal insulin with or without bolus), studies of patients on BOT excluding premixed studies, studies of insulin-naïve patients only, only studies with Week 24--28 results, and excluding degludec three times weekly (3TW) dosing. Meta-regression was conducted for key outcomes to account for study-level population characteristics, adjusting for the following: study-level baseline HbA1c, diabetes disease duration and basal-bolus population. In addition, broader definitions for hypoglycaemia were analysed. A comparison of NMA to classical meta-analysis in the base scenario (BOT) using an inverse variance-weighted method was also conducted.

Results {#s3}
=======

Systematic literature review {#s3a}
----------------------------

Over 4000 studies were identified for screening, of which 86 were identified for data extraction; from these, 41 studies were included in the NMA ([figure 1](#BMJOPEN2015009421F1){ref-type="fig"}A). A brief overview of these studies is provided in [table 1](#BMJOPEN2015009421TB1){ref-type="table"}.

###### 

Randomised comparative studies included in NMA of patients with T2DM on basal insulin treatment

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                First author, year published (Regimen type)                                           Countries/Continents                                                                  Key inclusion criteria   N\*                                                  Randomised comparator arms      Allocation method          Study duration                          Discontinuation rate†                 Outcomes in current NMA‡         
  ----------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------------- ------------------------------- -------------------------- --------------------------------------- ----------------------------------- -------------------------- --- --- ---
  Gla-300 vs Gla-100            Bolli, 2015[@R8]                                                                      North America, Europe, Japan                                                          Insulin naïve\           873                                                  Gla-300\                        IVRS                       6 months                                Gla-300: 62/439 (14%)\                                       ✓   ✓   ✓   ✓
                                                                                                                                                                                                            OAD\                                                                          Gla-100                                                                                            Gla-100: 75/439 (17%)                                                  
                                                                                                                                                                                                            HbA1c 7--11%                                                                                                                                                                                                                                            

  Riddle, 2014[@R6]             North America, Europe, South Africa                                                   On basal bolus insulin regimen\                                                       806                      Gla-300 + bolus\                                     IVRS                            6 months                   Gla-300: 30/404 (7.4%)\                 ✓                                                            ✓   ✓   ✓ 
                                                                                                                      HbA1c 7--10%                                                                                                   Gla-100 + bolus                                                                                                 Gla-100: 31/402 (7.7%)                                                                                         

  Yki-Järvinen, 2014[@R7]       North America, Europe, Russia, South America, South Africa                            On basal insulin\                                                                     809                      Gla-300\                                             IVRS                            6 months                   Gla-300: 36/404 (8.9%)\                 ✓                                                            ✓   ✓   ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 38/407 (9.3%)                                                                                         
                                                                                                                      HbA1c 7--10%                                                                                                                                                                                                                                                                                                                                  

  Gla-100 vs premixed insulin   Aschner, 2013[@R10]                                                                   NR                                                                                    Insulin naïve\           923                                                  Premixed\                       NR                         24 weeks                                NR (meeting abstract)                                        ✓   ✓       ✓
                                                                                                                                                                                                            OAD                                                                           Gla-100±glulisine                                                                                                                                                         

  Buse, 2009[@R11]              Australia, Europe, India, North America, South America                                Insulin naïve\                                                                        2091                     Lispro protamine/lispro 75/25\                       IVRS                            24 weeks                   Premixed insulin:145/1045 (13.9%)\      ✓                                                            ✓         
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 128/1046 (12.2%)                                                                                      
                                                                                                                      HbA1c \>7%                                                                                                                                                                                                                                                                                                                                    

  Fritsche, 2010[@R12]          Europe and Australia                                                                  Premixed insulin\                                                                     310                      70/30 NPH + bolus (regular or aspart)\               Electronic case record system   52 weeks                   Premixed insulin: 28/157 (17.8%)\       ✓                                                            ✓   ✓     
                                                                                                                      +/- Metformin\                                                                                                 Gla-100 + glulisine                                                                                             Gla-100:25/153 (16.3%)                                                                                         
                                                                                                                      HbA1c 7.5--11.0%                                                                                                                                                                                                                                                                                                                              

  Jain, 2010[@R13]              Asia, Australia, Europe, North America, Russian Federation                            Insulin naïve\                                                                        484                      Insulin lispro 50/50\                                TS                              36 weeks                   Premixed insulin: 31/242 (12.8%)\       ✓                                                            ✓         
                                                                                                                      OAD\                                                                                                           Gla-100 + lispro                                                                                                Gla-100: 27/242 (11.2%)                                                                                        
                                                                                                                      HbA1c ≥7.5--12%                                                                                                                                                                                                                                                                                                                               

  Kann, 2006[@R14]              Europe                                                                                Insulin naïve\                                                                        255                      Insulin aspart 70/30+ metformin\                     Sealed codes                    28 weeks                   Premixed insulin: 13/130 (10.0%)\       ✓                                                            ✓         
                                                                                                                      OAD\                                                                                                           Gla-100 + glimepiride                                                                                           Gla-100: 12/128 (9.4%)                                                                                         
                                                                                                                      HbA1c \>7--12%                                                                                                                                                                                                                                                                                                                                

  Kazda, 2006[@R15]             Germany                                                                               Insulin naïve\                                                                        159                      Protaminatedlispro/lispro 50/50\                     NR                              24 weeks                   Premixed insulin: 14.8%§\               ✓                                                            ✓         
                                                                                                                      HbA1c 6--10.5%                                                                                                 Lispro\                                                                                                         Bolus insulin: 7.7%§\                                                                                          
                                                                                                                                                                                                                                     Gla-100                                                                                                         Gla-100: 15.1%§                                                                                                

  Ligthelm, 2011[@R16]          USA and Puerto Rico                                                                   On basal insulin\                                                                     279                      Biphasic aspart 70/30\                               IVRS                            24 weeks                   Premixed insulin: 19/137 (13.9%)\       ✓                                                            ✓   ✓     
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 32/143 (22.4%)                                                                                        
                                                                                                                      HbA1c ≥8%                                                                                                                                                                                                                                                                                                                                     

  Raskin, 2005[@R17]            USA                                                                                   Insulin naïve\                                                                        222                      Biphasic aspart 70/30\                               Sequential numbers/codes        28 weeks                   Premixed insulin:17/117 (14.5%)\        ✓                                                                      
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 7/116 (6.0%)                                                                                          
                                                                                                                      HbA1c ≥8%                                                                                                                                                                                                                                                                                                                                     

  Riddle, 2011[@R18]            NR                                                                                    OAD                                                                                   572                      Protamine-aspart/aspart 70/30\                       NR                              60 weeks                   NR (meeting abstract)                   ✓                                                                    ✓ 
                                                                                                                                                                                                                                     Glargine + 1 prandial Glulisine\                                                                                                                                                                                               
                                                                                                                                                                                                                                     Gla-100 + glulisine (stepwise addition)                                                                                                                                                                                        

  Robbins, 2007[@R19]           Australia, Europe, India, North America (USA and Puerto Rico)                         OAD\                                                                                  315                      Lispro 50/50 + metformin\                            TS                              24 weeks                   Premixed insulin: 15/158 (9.5%)\        ✓                                                            ✓         
                                                                                                                      HbA1c 6.5--11%                                                                                                 Gla-100+metformin                                                                                               Gla-100: 22/159 (13.8%)                                                                                        

  Rosenstock, 2008[@R20]        USA and Puerto Rico                                                                   On basal insulin\                                                                     374                      Insulin lispro protamine/lispro\                     TS                              24 weeks                   Premixed insulin: 29/187 (15.5%)\       ✓                                                            ✓       ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100 + lispro                                                                                                Gla-100: 29/187 (15.5%)                                                                                        
                                                                                                                      HbA1c 7.5--12%                                                                                                                                                                                                                                                                                                                                

  Strojek, 2009[@R21]           Asia, Europe, North America, South America, South Africa                              Insulin naïve\                                                                        469                      Biphasic aspart 70/30 + metformin/glimepiride\       IVRS                            26 weeks                   Premixed insulin: 26/239 (10.9%)\       ✓                                                                ✓     
                                                                                                                      OAD\                                                                                                           Gla-100 +metformin/glimepiride                                                                                  Gla-100: 21/241 (8.7%)                                                                                         
                                                                                                                      HbA1c \>7--11%                                                                                                                                                                                                                                                                                                                                

  Tinahones, 2013[@R22]         11 countries (not specified)                                                          On basal insulin\                                                                     478                      Lispro mix 25/75\                                    NR                              24 weeks                   NR (meeting abstract)                   ✓                                                            ✓       ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100 + lispro                                                                                                                                                                                                               
                                                                                                                      HbA1c 7.5--10.5%                                                                                                                                                                                                                                                                                                                              

  Vora, 2013[@R23]              NR                                                                                    On basal insulin                                                                      335                      Biphasic insulin aspart/aspart protamine 30/70\      NR                              24 weeks                   Premixed insulin: 23/165 (13.9%)\       ✓                                                                    ✓ 
                                                                                                                                                                                                                                     Gla-100 + glulisine                                                                                             Gla-100: 14/170 (8.2%)                                                                                         

  Gla-100 vs NPH                Fritsche, 2003[@R24]                                                                  Europe                                                                                Insulin naïve\           695                                                  NPH\                            Sequential numbers/codes   28 weeks                                NPH: 27/234 (11.5%)\                                         ✓   ✓       ✓
                                                                                                                                                                                                            OAD\                                                                          Gla-100 (morning)\                                                                                 Gla-100 (morning): 12/237 (5.1%)\                                      
                                                                                                                                                                                                            HbA1c 7.5--10.5%                                                              Gla-100 (bedtime)                                                                                  Gla-100 (bedtime):18/229 (7.9%)                                        

  Massi Benedetti, 2003[@R25]   Europe, South Africa                                                                  OAD                                                                                   570                      NPH\                                                 Sequential numbers/codes        52 weeks                   NPH: 33/285(11.6%)\                     ✓                                                                    ✓ 
                                                                                                                                                                                                                                     Gla-100                                                                                                         Gla-100: 16/293 (5.5%)                                                                                         

  Riddle, 2003[@R26]            North America                                                                         Insulin naïve\                                                                        756                      NPH\                                                 IVRS                            24 weeks                   NPH: 32/392 (8.2%)\                     ✓                                                            ✓       ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 33/372 (8.9%)                                                                                         
                                                                                                                      HbA1c 7.5--10%                                                                                                                                                                                                                                                                                                                                

  Rosenstock, 2001[@R27]        NR                                                                                    On insulin\                                                                           518                      NPH\                                                 NR                              28 weeks                   NPH: 21/259 (8.1%)\                     ✓                                                            ✓       ✓ 
                                                                                                                      HbA1c 7--12%                                                                                                   Gla-100                                                                                                         Gla-100: 28/259 (10.8%)                                                                                        

  Rosenstock 2009[@R28]         North America                                                                         OAD\                                                                                  1017                     NPH\                                                 IVRS                            5 years                    NPH: 145/509 (28.5%)§\                  ✓                                                            ✓         
                                                                                                                      HbA1c 6--12%                                                                                                   Gla-100                                                                                                         Gla-100: 141/515 (27.4%)§                                                                                      

  Yki-Järvinen, 2006[@R29]      Europe                                                                                Insulin naïve\                                                                        110                      NPH\                                                 NR                              36 weeks                   NPH: 1/49 (2.0%)\                       ✓                                                            ✓       ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 1/61 (1.6%)                                                                                           
                                                                                                                      HbA1c ≥8%                                                                                                                                                                                                                                                                                                                                     

  Degludec vs Gla-100           Garber, 2012[@R30]                                                                    Asia (Hong Kong), Europe, Middle East (Turkey), North America, Russia, South Africa   On insulin\              1004                                                 Degludec + aspart\              IVRS                       52 weeks                                Degludec: 137/755 (18.1%)\                                   ✓   ✓   ✓   ✓
                                                                                                                                                                                                            ±OAD\                                                                         Gla-100 + aspart                                                                                   Glargine:40/251 (15.9%)                                                
                                                                                                                                                                                                            HbA1c 7--10%                                                                                                                                                                                                                                            

  Gough, 2013[@R31]             Europe, North America, Russia, South Africa                                           Insulin naïve\                                                                        456                      Degludec\                                            IVRS                            26 weeks                   NR§                                     ✓                                                            ✓   ✓   ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                                                                                                                                        
                                                                                                                      HbA1c 7--10%                                                                                                                                                                                                                                                                                                                                  

  Meneghini, 2013[@R32]         Asia, Europe, Israel, North America, Russia, South America, South Africa              OAD\                                                                                  685                      Degludec (flexible)\                                 IVRS                            26 weeks                   Degludec(flexible): 26/229 (11.4%)\     ✓                                                            ✓   ✓   ✓ 
                                                                                                                      HbA1c 7--11%                                                                                                   Degludec (once daily)\                                                                                          Degludec(once daily): 24/228 (10.5%)\                                                                          
                                                                                                                                                                                                                                     Gla-100                                                                                                         Gla-100: 27/230 (11.7%)                                                                                        

  Zinman, 2012[@R33]            Europe, North America                                                                 Insulin naïve\                                                                        1023                     Degludec\                                            IVRS                            52 weeks                   Degludec: 166/773 (21.5%)\              ✓                                                            ✓   ✓   ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Glargine:60/257 (23.3%)                                                                                        
                                                                                                                      HbA1c 7--10%                                                                                                                                                                                                                                                                                                                                  

  Zinman (AM), 2013[@R34]       Europe, Israel, North America, South Africa                                           Insulin naïve\                                                                        456                      Degludec\                                            IVRS                            26 weeks                   Degludec: 38/230 (16.5%)\               ✓                                                            ✓   ✓     
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 24/230 (10.4%)                                                                                        
                                                                                                                      HbA1c 7--10%                                                                                                                                                                                                                                                                                                                                  

  Zinman (PM), 2013[@R34]       Europe, North America                                                                 Insulin naïve\                                                                        467                      Degludec\                                            IVRS                            26 weeks                   Degludec: 25/233 (10.7%)\               ✓                                                            ✓   ✓     
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 25/234 (10.7%)                                                                                        
                                                                                                                      HbA1c 7--10%                                                                                                                                                                                                                                                                                                                                  

  Detemir vs Gla-100            Hollander, 2008[@R35]                                                                 Europe and the USA                                                                    OAD and/or insulin\      319                                                  Detemir + aspart\               TS                         52 weeks                                Detemir: 43/216 (19.9%)\                                     ✓   ✓   ✓ 
                                                                                                                                                                                                            HbA1c 7--11%                                                                  Gla-100 + aspart                                                                                   Gla-100: 23/107 (21.5%)                                                

  Meneghini, 2013[@R36]         Asia, South America, USA                                                              Insulin naïve\                                                                        453                      Detemir\                                             NR                              26 weeks                   Detemir: 38/228 (16.7%)\                ✓                                                            ✓   ✓     
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 41/229 (17.9%)                                                                                        
                                                                                                                      HbA1c 7--9%                                                                                                                                                                                                                                                                                                                                   

  Raskin, 2009[@R37]            NR                                                                                    OAD and/or insulin\                                                                   387                      Detemir + aspart\                                    NR                              26 weeks                   Detemir: 46/256 (18.0%)\                ✓                                                            ✓   ✓     
                                                                                                                      HbA1c 7--11%                                                                                                   Gla-100 + aspart                                                                                                Gla-100: 18/131 (13.7%)                                                                                        

  Rosenstock, 2008[@R38]        Europe and the USA                                                                    Insulin naïve\                                                                        582                      Detemir\                                             TS                              52 weeks                   Detemir: 60/291 (20.6%)\                ✓                                                            ✓   ✓     
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100: 39/291 (13.4%)                                                                                        
                                                                                                                      HbA1c 7.5--10%                                                                                                                                                                                                                                                                                                                                

  Swinnen, 2010[@R39]           Asia, Australia, Europe, Middle East (Turkey), North America, Russia, South America   Insulin naïve\                                                                        964                      Detemir\                                             NR                              24 weeks                   Detemir: 10.1%§\                        ✓                                                            ✓       ✓ 
                                                                                                                      OAD\                                                                                                           Gla-100                                                                                                         Gla-100:4.6%§                                                                                                  
                                                                                                                      HbA1c 7--10.5%                                                                                                                                                                                                                                                                                                                                

  Detemir vs premixed           Holman, 2007[@R40]                                                                    Europe                                                                                Insulin naïve\           708                                                  Prandial insulin aspart\        IVRS                       52 weeks                                Bolus: 17/239 (7.1%)\                                        ✓   ✓     
                                                                                                                                                                                                            OAD\                                                                          Detemir\                                                                                           Detemir: 10/234 (4.3%)\                                                
                                                                                                                                                                                                            HbA1c 7--10%                                                                  Biphasic aspart 30                                                                                 Premixed insulin:13/235 (5.5%)                                         

  Liebl, 2009[@R41]             Europe                                                                                OAD\                                                                                  715                      Detemir + aspart\                                    Codes                           26 weeks                   Detemir: 44/541 (8.1%)\                 ✓                                                            ✓         
                                                                                                                      HbA1c 7--12%                                                                                                   Soluble aspart/protamine-crystallised aspart 30/70                                                              Premixed insulin: 17/178 (9.6%)                                                                                

  Detemir vs NPH                Haak, 2005[@R42]                                                                      Europe                                                                                HbA1c ≤12%               505                                                  Detemir + aspart\               NR                         26 weeks                                Detemir: 26/341 (7.6%)§\                                     ✓   ✓     
                                                                                                                                                                                                                                                                                          NPH + aspart                                                                                       NPH: 8/164 (4.9%)§                                                     

  Hermansen, 2006[@R43]         Europe                                                                                Insulin naïve\                                                                        475                      Detemir\                                             TS                              24 weeks                   Detemir: 4%§\                           ✓                                                            ✓   ✓     
                                                                                                                      OAD\                                                                                                           NPH                                                                                                             NPH: 5%§                                                                                                       
                                                                                                                      HbA1c 7.5--10%                                                                                                                                                                                                                                                                                                                                

  Montañana, 2008[@R44]         Spain                                                                                 On insulin± metformin\                                                                271                      Detemir + aspart\                                    Codes                           26 weeks                   Detemir:7/126 (5.6%)\                   ✓                                                            ✓   ✓     
                                                                                                                      HbA1c 7.5--11%                                                                                                 NPH + aspart                                                                                                    NPH: 12/151 (7.9%)                                                                                             

  Philis-Tsimakas, 2006[@R45]   North America and Europe                                                              Insulin naïve\                                                                        498                      Detemir morning\                                     IVRS                            20 weeks                   Detemir (morning): 19/168 (11.3%)\      ✓                                                                ✓     
                                                                                                                      OAD\                                                                                                           Detemir evening\                                                                                                Detemir (evening): 16/170 (9.4%)\                                                                              
                                                                                                                      HbA1c 7.5--11%                                                                                                 NPH                                                                                                             NPH: 17/166 (10.2%)                                                                                            

  Raslová, 2004[@R46]           8 Countries (not specified)                                                           On insulin\                                                                           394                      Detemir + insulin aspart\                            NR                              22 weeks                   Detemir: 10/195 (5.1%)§\                ✓                                                            ✓         
                                                                                                                      ±OADs\                                                                                                         NPH + human soluble insulin                                                                                     NPH: 6/199 (3.0%)§                                                                                             
                                                                                                                      HbA1c \<12%                                                                                                                                                                                                                                                                                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All the studies were open-label, with the exception of Liebl *et al*[@R1] (not reported).

\*Safety population; exceptions: efficacy population for Buse *et al*,[@R11] Raslová *et al*,[@R46] Riddle *et al*,[@R18] Tinahones *et al*[@R22] and Vora *et al*.[@R23]

†Numerator for discontinuation rate=randomised patients−patients completing the study; denominator for discontinuation rate=randomised patients. Exceptions noted in footnote (§).

‡A=change in HbA1c, B=change in body weight, C=nocturnal hypoglycaemia rate, D=documented symptomatic hypoglycaemia rate.

§Exceptions to definition of discontinuation rate/or discontinuation rate not calculable with information available: Gough 2013 reported that 460 were randomised 1:1 (3 were randomised in error and were withdrawn, 1 withdrew consent (all prior to treatment)) and 228 and 229 received detemir and Gla-100, respectively, however, completion/withdrawal not described; Kazda *et al*[@R15] reported 'drop-out' rates (however, numbers randomised to each group not provided and denominator may have been exposed rather than randomised patients); Swinnen *et al*\'s[@R39] brief report does not make clear what the denominator was for completion rate provided (did not report number randomised to each group, only total randomised; did not report numbers of patients completing the study---only the percentages); Hermansen *et al*:[@R43] denominator may be ITT population---475 were randomised but the breakdown between treatment arms is not clear; Haak *et al*,[@R42] reported rates based on patients receiving treatment rather than randomised patients; Raslová *et al*[@R46] reported rates reported based on ITT rather than randomised patients (ITT only 1 less than randomised, but number randomised to each treatment arm not provided in publication). In addition, Rosenstock *et al*[@R28] reported data over 5 years; however, only the first year data were included in this NMA.

HbA1c, glycated haemoglobin; ITT, intention to treat; IVRS, interactive voice (or web) response system; NMA, network meta-analysis; NPH, neutral protamine Hagedorn;

NR, not reported; OAD,oral antidiabetic medication; T2DM, type 2 diabetes mellitus; TS, telephone system.

![(A) PRISMA flow diagram for studies comparing basal insulin therapies in type 2 diabetes mellitus (T2DM; N=41). ^a^Cochrane Library (eg, the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effectiveness (DARE)), MEDLINE and MEDLINE In-Process (using Ovid platform), Embase (using Ovid Platform) and PsycINFO; If applicable, relevant results from clinical trial registry were included. Zinman *et al*[@R34] report 2 distinct studies within 1 publication. ^b^For title/abstract and full-text review, articles were excluded based on inclusion/exclusion criteria as specified in the systematic literature review. ^c^Two articles analysed the same trial. ^d^Conferences searched included EASD and ADA 2011--2013, and IDF 2011. IDF 2013 was assessed when the CD-ROM became available---the end of February. Multiple abstracts examined the same trial and 14 trials were extracted. ^e^Studies must include at least two treatment arms in the network, including: U300, insulin glargine, insulin detemir, insulin NPH, insulin degludec and premix insulin. (B) Evidence network diagram for BOT studies (n=25) reporting HbA1c (%) change from baseline. Each insulin treatment is a node in the network. The links between the nodes represent direct comparisons. The numbers along the lines indicate the number of trials or pairs of trial arms for that link in the network. Reference numbers indicate the trials contributing to each link. BOT, basal insulin-supported oral therapy; HbA1c, glycated haemoglobin; NPH, neutral protamine Hagedorn.](bmjopen2015009421f01){#BMJOPEN2015009421F1}

Included trials {#s3b}
---------------

All studies were randomised based on entry criteria, with interactive voice (or web) response system or telephone system as the main method of randomisation (n=22), followed by use of sequential numbers/codes (n=6) and electronic case record system (n=1); the method of randomisation was either not reported or not clear in the remaining studies (n=12). The majority (40/41) of studies specified an open-label in design (1 study did not specify). Loss to follow-up (ie, rates of discontinuation among randomised patients) among the studies ranged from 1.6% to 28.5%, with 10 studies reporting discontinuation rates \<10%, 22 reporting 10--20% and 5 reporting \>20% in at least one treatment arm (loss to follow-up was not reported in 4 studies). The baseline patient characteristics of patients in each of the 41 studies are provided in [table 2](#BMJOPEN2015009421TB2){ref-type="table"}.

###### 

Patient baseline characteristics for trials included in the NMA (N=41)

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                          First author      Year        Age\        Male (%)     Diabetes duration (years)\   HbA1c (%), Mean±SD   Body weight (kg)\
                                                        Mean±SD                  Mean±SD                                           Mean±SD
  ----------------------- ----------------- ----------- ----------- ------------ ---------------------------- -------------------- -------------------
  Gla-100 vs Gla-300      Bolli[@R8]        2015        57.7±10.1   57.8         9.8±6.4                      8.5±1.1              95.4±23.0

  Riddle[@R6]             2014              60.0±8.6    52.9        15.9±7.5     8.1±0.8                      106.3±20.8           

  Yki-Järvinen[@R7]       2014              58.2±9.2    45.9        12.6±7.1     8.3±0.8                      98.4±21.6            

  Gla-100 vs premixed     Aschner[@R10]     2013        NA          NA           NA                           8.7±0                NA

  Buse[@R11]              2009              57.0±10     52.80       9.5±6.1      9.1±1.3                      88.50±21.0           

  Fritsche[@R12]          2010              60.6±7.7    50.91       12.7±6.3     8.6±0.9                      85.61±15.1           

  Jain[@R13]              2010              59.4±9.2    48.78       11.7±6.5     9.4±1.2                      78.5±15.3            

  Kann[@R14]              2006              61.3±9.1    51.4        10.25±7.1    9.1±1.4                      85.4±15.5            

  Kazda[@R15]             2006              59.4±9.5    54.7        5.6±2.9      8.1±1.2                      NA                   

  Ligthelm[@R16]          2011              52.7±10.4   56.66       11.15±6.4    9.0±1.1                      97.9±20.5            

  Raskin[@R17]            2005              52.5±10.2   54.5        9.2±5.3      9.8±1.5                      90.2±18.9            

  Riddle[@R18]            2011              NA          NA          NA           NA                           NA                   

  Robbins[@R19]           2007              57.8±9.1    49.9        11.9±6.3     7.8±1.0                      88.6±19.7            

  Rosenstock[@R20]        2008              54.7±9.5    52.5        11.1±6.3     8.9±1.1                      99.5±20.6            

  Strojek[@R21]           2009              56.0±9.9    43.96       9.3±6.0      8.5±1.1                      NA                   

  Tinahones[@R22]         2013              NA          NA          NA           8.6±0.8                      NA                   

  Vora[@R23]              2013              NA          NA          NA           NA                           NA                   

  Gla-100 vs NPH          Fritsche[@R24]    2003        61.0±9.0    53.7         NA                           9.1±1.0              81.3±14.8

  MassiBenedetti[@R25]    2003              59.5±9.2    53.7        10.35±6.1    9.0±1.2                      NA                   

  Riddle[@R26]            2003              55.5±9.2    55.5        8.71±5.56    8.6±0.9                      NA                   

  Rosenstock[@R27]        2001              59.4±9.8    60.1        13.75±8.65   8.6±1.2                      90.2±17.6            

  Rosenstock[@R28]        2009              55.1±8.7    53.9        10.75±6.8    8.4±1.4                      99.5±22.5            

  Yki-Järvinen[@R29]      2006              56.5±1      63.3        9±1          9.5±0.1                      93.1±2.5             

  Degludec vs Gla-100     Garber[@R30]      2012        58.9±9.3    54.0         13.6±7.3                     8.3±0.8              92.5±17.7

  Gough[@R31]             2013              57.6±9.2    53.2        8.2±6.2      8.3±1.0                      92.5±18.5            

  Meneghini[@R32]         2013              56.5±9.6    53.7        10.6±6.7     8.4±0.9                      81.7±16.7            

  Zinman[@R33]            2012              59.2±9.8    61.9        9.2±6.2      8.2±0.8                      90.0±17.3            

  Zinman (PM)[@R34]       2013              57.4±10.2   57.2        8.8±3.4      8.3±0.8                      91.9±18.5            

  Zinman (AM)[@R34]       2013              58.2±9.8    56.9        8.9±6.1      8.3±0.9                      93.3±18.8            

  Detemir vs Gla-100      Hollander[@R35]   2008        58.7±11     58.0         13.5±8.0                     8.7±1.0              92.7±17.6

  Meneghini[@R36]         2013              57.3±10.3   56.5        8.2±6.1      7.91±0.6                     82.3±16.7            

  Raskin[@R37]            2009              55.8±10.3   54.6        12.3±7.0     8.4±1                        95.6±18.2            

  Rosenstock[@R38]        2008              58.9±9.9    57.9        9.1±6.3      8.6±0.8                      87.4±17.0            

  Swinnen[@R39]           2010              58.4±8.3    54.7        9.9±5.8      8.7±0.9                      83.9±17.1            

  Detemir vs premixed     Holman[@R40]      2007        61.7±9.8    64.1         NA                           8.5±0.8              85.8±15.9

  Liebl[@R41]             2009              60.7±9.2    58.5        9.3±6.4      8.5±1.1                      NA                   

  Detemir vs NPH          Haak[@R42]        2005        60.4±8.6    51.1         13.2±7.6                     7.9±1.3              86.9±15.8

  Hermansen[@R43]         2006              60.9±9.2    53.1        9.7±6.4      8.6±0.8                      82.6±13.8            

  Montañana[@R44]         2008              61.9±8.8    40.6        16.3±8.0     8.85±1.0                     81.0±12.1            

  Philis-Tsimakas[@R45]   2006              58.5±10.5   56.8        10.3±7.2     9.0±1.0                      NA                   

  Raslová[@R46]           2004              58.3±9.3    42.1        14.1±7.8     8.1±1.3                      80.8±12.7            
  ----------------------------------------------------------------------------------------------------------------------------------------------------

HbA1c, glycated haemoglobin; NA, not applicable; NMA, network meta-analysis; NPH, neutral protamine Hagedorn.

Twenty-five of the 41 studies (61%) were of patients on BOT (main population for this analysis; n=15 746 patients). The evidence network for the BOT studies is depicted in [figure 1](#BMJOPEN2015009421F1){ref-type="fig"}B. Patients in the BOT studies had a mean age ranging from 52.4 to 61.7 years, duration of diabetes 8.2--13.8 years, baseline body weight 81.3--99.5 kg and HbA1c 7.8--9.8%.

Glycaemic control {#s3c}
-----------------

In patients with T2DM on BOT (n=25 studies), the change in HbA1c was comparable between Gla-300 and insulin detemir (−0.08; −0.40 to 0.24), neutral protamine Hagedorn (NPH; 0.01; −0.28 to 0.32), degludec (−0.12; −0.42 to 0.20) and premixed insulin (0.26; −0.04 to 0.58) ([figure 2](#BMJOPEN2015009421F2){ref-type="fig"}A). These changes were similar to those in the overall NMA (n=41 studies) and across the various sensitivity analyses shown in [table 3](#BMJOPEN2015009421TB3){ref-type="table"}A.

###### 

Additional analyses

  \(A\) Sensitivity analyses                                                                                                                        
  ------------------------------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ------------------------
  Change in HbA1c\*                                                                                                                                 
   BOT, insulin naïve                               0.01 (−0.27 to 0.29)    −0.14 (−0.47 to 0.19)   −0.09 (−0.43 to 0.25)   −0.12 (−0.45 to 0.21)   0.08 (−0.23 to 0.39)
   Adjusting for Bolus Insulin Trials               −0.01 (−0.44 to 0.42)   −0.10 (−0.55 to 0.36)   −0.05 (−0.51 to 0.41)   −0.14 (−0.60 to 0.33)   0.07 (−0.37 to 0.51)
   Insulin naïve                                    0.04 (−0.41 to 0.48)    −0.09 (−0.59 to 0.40)   −0.06 (−0.55 to 0.43)   −0.12 (−0.62 to 0.37)   0.24 (−0.22 to 0.72)
   T2DM overall                                     0.01 (−0.23 to 0.25)    −0.08 (−0.37 to 0.21)   −0.03 (−0.32 to 0.26)   −0.12 (−0.42 to 0.18)   0.09 (−0.18 to 0.35)
   Studies reporting hypoglycaemia data             0.01 (−0.23 to 0.25)    −0.18 (−0.51 to 0.14)   −0.09 (−0.57 to 0.38)   −0.12 (−0.42 to 0.18)   0.18 (−0.12 to 0.51)
   Studies with 24--28-week results                 0.01 (−0.24 to 0.26)    −0.04 (−0.36 to 0.27)   −0.03 (−0.35 to 0.30)   −0.14 (−0.47 to 0.19)   0.17 (−0.10 to 0.45)
   Excluding Degludec 3TW                           0.02 (−0.22 to 0.28)    −0.08 (−0.37 to 0.22)   0.01 (−0.26 to 0.30)    −0.01 (−0.32 to 0.31)   0.26 (−0.02 to 0.55)
   Adjusting for baseline HbA1c                     0.05 (−0.49 to 0.63)    −0.03 (−0.60 to 0.56)   0.02 (−0.56 to 0.61)    −0.07 (−0.65 to 0.53)   0.13 (−0.42 to 0.72)
   Adjusting for disease duration                   0.03 (−0.29 to 0.34)    −0.06 (−0.41 to 0.29)   −0.01 (−0.37 to 0.35)   −0.10 (−0.46 to 0.26)   0.11 (−0.23 to 0.44)
  Change in body weight                                                                                                                             
   BOT, insulin naïve                               −0.44 (−1.67 to 0.81)   0.58 (−0.85 to 2.03)    −0.22 (−1.68 to 1.25)   −0.52 (−1.93 to 0.92)   −1.09 (−2.44 to 0.29)
   Adjusting for Bolus Insulin Trials               −0.58 (−2.54 to 1.37)   0.11 (−1.98 to 2.20)    −0.63 (−2.75 to 1.45)   −0.66 (−2.78 to 1.45)   −1.13 (−3.18 to 0.91)
   Insulin naïve                                    −0.30 (−1.44 to 0.82)   1.18 (−0.12 to 2.47)    −0.12 (−1.39 to 1.10)   −0.46 (−1.71 to 0.80)   −1.12 (−2.39 to 0.15)
   T2DM overall                                     −0.27 (−1.28 to 0.73)   0.42 (−0.78 to 1.62)    −0.32 (−1.54 to 0.89)   −0.35 (−1.58 to 0.88)   −0.81 (−1.96 to 0.32)
   Studies reporting hypoglycaemia data             −0.28 (−1.28 to 0.71)   1.01 (−0.29 to 2.31)    0.89 (−0.90 to 2.70)    −0.36 (−1.58 to 0.86)   −1.24 (−2.59 to 0.09)
   Studies with 24--28-week results                 −0.28 (−1.28 to 0.74)   0.26 (−1.05 to 1.57)    −0.15 (−1.45 to 1.16)   −0.42 (−1.76 to 0.92)   −1.01 (−2.19 to 0.18)
   Excluding Degludec 3TW                           −0.46 (−1.34 to 0.43)   0.68 (−0.38 to 1.76)    −0.76 (−1.82 to 0.27)   −0.79 (−1.90 to 0.33)   −1.83 (−2.89 to −0.68)
   Adjusting for baseline HbA1c                     −0.27 (−2.03 to 1.25)   0.43 (−1.46 to 2.12)    −0.32 (−2.23 to 1.39)   −0.34 (−2.26 to 1.38)   −0.81 (−2.68 to 0.82)
   Adjusting for disease duration                   −0.44 (−1.91 to 1.00)   0.25 (−1.38 to 1.87)    −0.49 (−2.15 to 1.13)   −0.52 (−2.20 to 1.13)   −0.99 (−2.58 to 0.58)
  Nocturnal hypoglycaemia event rate                                                                                                                
   BOT, insulin naïve                               0.57 (0.33 to 0.98)     0.53 (0.28 to 1.01)     0.21 (0.10 to 0.44)     0.68 (0.36 to 1.25)     0.42 (0.21 to 0.81)
   BOT, premixed excluded                           0.62 (0.37 to 1.17)     0.56 (0.30 to 1.21)     0.16 (0.08 to 0.41)     0.79 (0.42 to 1.64)     N/A
   Adjusting for Bolus Insulin Trials               0.56 (0.24 to 1.29)     0.52 (0.21 to 1.32)     0.20 (0.07 to 0.57)     0.66 (0.26 to 1.61)     0.50 (0.19 to 1.26)
   Insulin naïve patients only                      0.58 (0.12 to 2.77)     0.51 (0.07 to 3.38)     0.17 (0.02 to 1.37)     0.61 (0.10 to 3.48)     0.26 (0.03 to 2.35)
   T2DM overall                                     0.64 (0.39 to 1.03)     0.60 (0.32 to 1.11)     0.23 (0.11 to 0.50)     0.75 (0.41 to 1.34)     0.57 (0.31 to 1.05)
   Studies with 24--28-week results                 0.64 (0.37 to 1.10)     0.51 (0.22 to 1.18)     0.24 (0.08 to 0.70)     0.67 (0.32 to 1.37)     0.55 (0.26 to 1.17)
   Excluding Degludec 3TW                           0.57 (0.33 to 0.98)     0.51 (0.24 to 1.07)     0.19 (0.07 to 0.45)     0.83 (0.42 to 1.69)     0.36 (0.17 to 0.74)
   2.8--4.2 mmol/L                                  0.64 (0.37 to 1.11)     0.68 (0.35 to 1.34)     0.31 (0.15 to 0.63)     0.75 (0.38 to 1.46)     0.68 (0.35 to 1.29)
   Adjusting for baseline HbA1c                     0.37 (0.18 to 0.90)     0.35 (0.15 to 0.91)     0.13 (0.05 to 0.39)     0.43 (0.19 to 1.12)     0.33 (0.14 to 0.86)
   Adjusting for disease duration                   0.60 (0.31 to 1.13)     0.56 (0.26 to 1.19)     0.22 (0.09 to 0.53)     0.71 (0.34 to 1.46)     0.54 (0.25 to 1.14)
  Documented symptomatic hypoglycaemia event rate                                                                                                   
   BOT, insulin naïve                               0.72 (0.40 to 1.30)     0.63 (0.22 to 1.73)     0.58 (0.26 to 1.24)     0.59 (0.29 to 1.20)     0.50 (0.24 to 1.01)
   BOT, premixed excluded                           0.75 (0.55 to 1.05)     0.69 (0.42 to 1.23)     0.55 (0.36 to 0.91)     0.66 (0.46 to 1.01)     N/A
   Adjusting for Bolus Insulin Trials               0.83 (0.35 to 1.83)     0.72 (0.22 to 2.31)     0.76 (0.28 to 1.86)     0.68 (0.26 to 1.67)     0.57 (0.22 to 1.41)
   Insulin naïve patients only                      0.62 (0.21 to 1.77)     0.54 (0.12 to 2.36)     0.50 (0.14 to 1.63)     0.61 (0.17 to 2.25)     0.24 (0.05 to 1.09)
   T2DM overall                                     0.78 (0.50 to 1.23)     0.68 (0.27 to 1.70)     0.71 (0.38 to 1.30)     0.64 (0.36 to 1.16)     0.54 (0.30 to 0.98)
   Studies with 24--28-week results                 0.78 (0.45 to 1.34)     0.68 (0.23 to 2.01)     0.75 (0.36 to 1.60)     0.53 (0.23 to 1.20)     0.58 (0.27 to 1.25)
   Adjusting for baseline HbA1c                     0.71 (0.44 to 1.13)     0.61 (0.25 to 1.51)     0.64 (0.34 to 1.19)     0.58 (0.32 to 1.05)     0.49 (0.27 to 0.89)
   Adjusting for disease duration                   0.57 (0.32 to 0.99)     0.50 (0.18 to 1.33)     0.52 (0.25 to 1.04)     0.47 (0.23 to 0.92)     0.40 (0.19 to 0.78)

  \(B\) Comparison of NMA to classic meta-analysis for base scenario (BOT)                                                     
  -------------------------------------------------------------------------- ------------------------ ------------------------ ------------------------
  Change in HbA1c†                                                           Gla-300 vs Gla-100       0.01 (−0.27 to 0.29)     0.02 (−0.08 to 0.11)
  Insulin detemir vs Gla-100                                                 0.10 (−0.07 to 0.28)     0.04 (−0.05 to 0.13)     
  NPH vs Gla-100                                                             0.01 (−0.14 to 0.16)     0.02 (−0.05 to 0.09)     
  Insulin degludec vs Gla-100                                                0.14 (−0.03 to 0.30)     0.13 (0.06 to 0.20)      
  Premixed vs Gla-100                                                        −0.24 (−0.40 to −0.08)   −0.15 (−0.21 to −0.10)   
  Change in body weight                                                      Gla-300 vs Gla-100       −0.44 (−1.67 to 0.81)    −0.48 (−0.83 to −0.13)
  Insulin detemir vs Gla-100                                                 −1.15 (−1.73 to −0.58)   −0.98 (−1.20 to −0.76)   
  NPH vs Gla-100                                                             0.30 (−0.21 to 0.84)     0.01 (−0.22 to 0.25)     
  Insulin degludec vs Gla-100                                                0.18 (−0.35 to 0.70)     0.21 (0.03 to 0.38)      
  Premixed vs Gla-100                                                        1.37 (0.72 to 1.97)      1.70 (1.69 to 1.71)      
  Nocturnal hypoglycaemia event rate                                         Gla-300 vs Gla-100       0.57 (0.33 to 0.98)      0.59 (0.38 to 0.90)
  Insulin detemir vs Gla-100                                                 1.11 (0.58 to 2.10)      1.06 (0.93 to 1.21)      
  NPH vs Gla-100                                                             3.04 (1.24 to 7.80)      NA†                      
  Insulin degludec vs Gla-100                                                0.88 (0.57 to 1.38)      0.79 (0.67 to 0.93)      
  Premixed vs Gla-100                                                        1.60 (0.84 to 3.10)      1.39 (1.19 to 1.62)      
  Documented symptomatic hypoglycaemia event rate                            Gla-300 vs Gla-100       0.72 (0.40 to 1.30)      0.75 (0.61 to 0.92)
  Insulin detemir vs Gla-100                                                 1.15 (0.44 to 2.96)      1.15 (1.07 to 1.24)      
  NPH vs Gla-100                                                             1.10 (0.68 to 1.89)      1.04 (1.00 to 1.09)      
  Insulin degludec vs Gla-100                                                1.30 (0.75 to 2.24)      1.35 (1.27 to 1.44)      
  Premixed vs Gla-100                                                        NA†                      NA†                      

\*Four additional studies were included in sensitivity analyses for HbA1c and/or body weight, but were not in the main NMA.[@R47]

†No direct evidence for specific comparison.

BOT, basal insulin-supported oral therapy (ie, no bolus insulin); CrI, Credible interval; HbA1c, glycated haemoglobin; NA, not applicable; NMA, network meta-analysis; NPH, neutral protamine Hagedorn; T2DM, type 2 diabetes mellitus.

![NMA findings for Gla-300 versus other basal insulins in the BOT population: (A) change in HbA1c (%); (B) change in body weight (kg); (C) risk of nocturnal hypoglycaemia; (D) risk of documented symptomatic hypoglycaemia. BOT, basal insulin-supported oral therapy; CrI, credible interval; DET, =insulin detemir; DEG, insulin degludec; HbA1c, glycated haemoglobin; NMA, network meta-analysis; NPH, neutral protamine Hagedorn; PREMIX, premixed insulin; RR, risk ratio.](bmjopen2015009421f02a){#BMJOPEN2015009421F2}

![Continued](bmjopen2015009421f02b){#BMJOPEN2015009421F02B}

Body weight {#s3d}
-----------

Change in body weight from baseline was reported in 36 trials in the NMA. Among patients with T2DM on BOT, no statistically significant difference in body weight change was observed between Gla-300 and detemir (difference: 0.69; 95% CrI −0.31 to 1.71), NPH (−0.76; −1.75 to 0.21) or degludec (−0.63; −1.63 to 0.35), whereas weight gain was significantly lower with Gla-300 compared with premixed insulin (−1.83; −2.85 to −0.75) ([figure 2](#BMJOPEN2015009421F2){ref-type="fig"}B). These changes were similar to those in the overall NMA (n=41 studies) and across the various sensitivity analyses ([table 3](#BMJOPEN2015009421TB3){ref-type="table"}A).

Hypoglycaemia events {#s3e}
--------------------

Among the studies identified, 20 trials reported nocturnal hypoglycaemia event rate data and 16 reported documented symptomatic hypoglycaemia event rate data that met criteria for inclusion in the NMA. The hypoglycaemia event data from each of these clinical trials are summarised in [table 4](#BMJOPEN2015009421TB4){ref-type="table"}.

###### 

Hypoglycaemia outcomes for trials included in the NMA

  Study                            Year   Arm                                  Total exposure\*   Documented symptomatic   Nocturnal   Severe†
  -------------------------------- ------ ------------------------------------ ------------------ ------------------------ ----------- ---------
  Gla-100 vs Gla-300                                                                                                                   
   Bolli *et al*[@R8]              2013   Gla-100                              218                821                      41          4
  Gla-300                          217    505                                  24                 4                                    
   Riddle *et al*[@R6]             2014   Gla-100                              200                2957                     162         48
  Gla-300                          201    2714                                 127                54                                   
   Yki-Järvinen *et al*[@R7]       2014   Gla-100                              202                1641                     140         12
  Gla-300                          201    1357                                 78                 6                                    
  Gla-100 vs premixed insulin                                                                                                          
   Aschner *et al*[@R10]           2013   Gla-100                              213                249                                  5
  Premixed insulin                 212    632                                                     3                                    
   Fritsche *et al*[@R12]          2010   Gla-100                              141                                         321         16
  Premixed insulin                 149                                         353                33                                   
   Ligthelm *et al*[@R16]          2011   Gla-100                              65                                          233         6
  Premixed insulin                 63                                          273                0                                    
   Raskin *et al*[@R17]            2005   Gla-100                              61                                                      1
  Premixed insulin                 58                                                             0                                    
   Riddle *et al*[@R18]            2011   Gla-100 (plus step-wise glulisine)   220                1559                                 
  Gla-100 (plus 1 prandial dose)   217    1565                                                                                         
  Premixed insulin                 221    2694                                                                                         
   Robbins *et al*[@R19]           2007   Gla-100                              73                                                      4
  Premixed insulin                 72                                                             8                                    
   Rosenstock *et al*[@R20]        2008   Gla-100                              86                 3866                                 3
  Premixed insulin                 86     4000                                                    9                                    
   Strojek *et al*[@R21]           2009   Gla-100                              114                                         57          3
  Premixed insulin                 110                                         120                3                                    
   Tinahones *et al*[@R22]         2013   Gla-100                              111                859                                  
  Premixed insulin                 109    783                                                                                          
   Vora *et al*[@R23]              2013   Gla-100                              78                                          446         
  Premixed insulin                 76                                          273                                                     
  Gla-100 vs NPH                                                                                                                       
   Fritsche *et al*[@R24]          2003   Gla-100 (morning dosing)             109                710                                  6
  Gla-100 (evening dosing)         104    467                                                     4                                    
  NPH                              107    583                                                     13                                   
   Riddle *et al*[@R26]            2003   Gla-100                              169                1553                                 14
  NPH                              179    2308                                                    9                                    
   Rosenstock *et al*[@R27]        2001   Gla-100                              139                2012                                 
  NPH                              139    1577                                                                                         
   Rosenstock *et al*[@R28]        2009   Gla-100                              2556                                                    102
  NPH                              2511                                                           151                                  
   Yki-Järvinen *et al*[@R29]      2006   Gla-100                              42                 5                                    0
  NPH                              34     8                                                       0                                    
  Degludec vs Gla-100                                                                                                                  
   Garber *et al*[@R30]            2012   Degludec                             671                13 821                   932         40
  Gla-100                          229    5361                                 421                11                                   
   Gough *et al*[@R31]             2013   Degludec                             106                357                      19          0
  Gla-100                          107    389                                  30                 0                                    
   Meneghini *et al*[@R32]         2013   Degludec (flexible dosing)‡          108                851                      65          2
  Degludec (evening dosing)        105    776                                  63                 2                                    
  Gla-100                          105    383                                  84                 2                                    
   Zinman *et al*[@R33]            2012   Degludec                             667                2675                     167         2
  Gla-100                          218    806                                  85                 5                                    
   Zinman (AM) *et al*[@R34]       2013   Degludec                             105                                         42          1
  Gla-100                          106                                         21                 1                                    
   Zinman (PM) *et al*[@R34]       2013   Degludec                             109                                         22          1
  Gla-100                          110                                         22                 0                                    
  Detemir vs Gla-100                                                                                                                   
   Hollander *et al*[@R35]         2008   Detemir                              187                                         449         17
  Gla-100                          92                                          265                6                                    
   Meneghini *et al*[@R36]         2013   Detemir                              103                                         115         0
  Gla-100                          104                                         91                 2                                    
   Raskin *et al*[@R37]            2009   Detemir                              128                                         540         11
  Gla-100                          65                                          221                8                                    
   Rosenstock *et al*[@R38]        2008   Detemir                              262                                         341         0
  Gla-100                          269                                         350                0                                    
   Swinnen *et al*[@R39]           2010   Detemir                              224                1491                                 18
  Gla-100                          220    1273                                                    35                                   
  Detemir vs premixed insulin                                                                                                          
   Holman *et al*[@R40]            2007   Detemir                              233                                                     4
  Premixed insulin                 234                                                            11                                   
  Aspart                           238                                                            16                                   
  Detemir vs NPH                                                                                                                       
   Hermansen *et al*[@R43]         2006   Detemir                              106                                         160         1
  NPH                              106                                         349                8                                    
   Montañana *et al*[@R44]         2008   Detemir                              62                                          46          0
  NPH                              73                                          107                3                                    
   Philis-Tsimikas *et al*[@R45]   2006   Detemir (morning dosing)             63                                          6           0
  Detemir (evening dosing)         65                                          19                 2                                    
  NPH                              63                                          47                 0                                    

\*Total exposure indicates the number of patient-years over which the rate for hypoglycaemic events is determined.

†Although severe events were not analysed in the NMA due to small numbers of events, they are included in the table if reported within the publication.

‡Rotating morning and evening dosing schedule (ie, 8--40 h intervals between doses).

NMA, network meta-analysis; NPH, neutral protamine Hagedorn.

### Nocturnal hypoglycaemia {#s3e1}

In patients with T2DM on BOT, Gla-300 was associated with a significantly lower nocturnal hypoglycaemia rate compared with NPH (0.18; 0.05 to 0.55) and premixed insulin (0.36; 0.14 to 0.94) and a numerically lower rate when compared with detemir (0.52; 0.19 to 1.36) and degludec (0.66; 0.28 to 1.50) ([figure 2](#BMJOPEN2015009421F2){ref-type="fig"}C). These changes were similar to those in the overall NMA (n=41 studies) and across the various sensitivity analyses ([table 3](#BMJOPEN2015009421TB3){ref-type="table"}A).

### Documented symptomatic hypoglycaemia {#s3e2}

In patients with T2DM on BOT, Gla-300 was associated with a numerically lower rate of documented symptomatic hypoglycaemic events compared with detemir (0.63; 0.19 to 2.00), NPH (0.66; 0.27 to 1.49) and degludec (0.55; 0.23 to 1.34) ([figure 2](#BMJOPEN2015009421F2){ref-type="fig"}D). These changes were similar to those in the overall NMA (n=41 studies) and across the various sensitivity analyses ([table 3](#BMJOPEN2015009421TB3){ref-type="table"}A). In the BOT population, comparative data for premixed insulin were not available for this particular outcome.

### Comparison of NMA to classic meta-analysis findings {#s3e3}

The comparison of NMA results that integrate all available evidence versus those from classical meta-analysis solely based on direct evidence in the base scenario (BOT) found generally consistent effect size across all four outcomes and tighter 95% CIs with the classical meta-analysis ([table 3](#BMJOPEN2015009421TB3){ref-type="table"}B).

Discussion {#s4}
==========

In this NMA of randomised clinical studies comparing various basal insulin therapies in patients with T2DM, the new concentrated formulation, Gla-300, demonstrated change in HbA1c that was comparable to the change reported in studies of insulin detemir, degludec, NPH and premixed insulin. Change in body weight with Gla-300 was significantly less than that with premixed insulin and comparable to the other basal insulin. Hypoglycaemia rates appeared lower with Gla-300 and the comparator basal insulin. The rate of documented symptomatic hypoglycaemia associated with Gla-300 was numerically but not significantly different from that of other basal insulin therapies. A notable difference was that Gla-300 was associated with a significantly lower risk of nocturnal hypoglycaemia (ranging from approximately 64% to 82% lower) compared with premixed insulin and NPH.

These NMA data extend our current knowledge regarding Gla-300. Based on direct comparisons in the EDITION studies, Gla-300 was associated with comparable glycaemic control, but had a significantly lower rate of nocturnal hypoglycaemia compared with Gla-100.[@R6] The more flat and more prolonged pharmacokinetic profile associated with Gla-300 compared with Gla-100 may contribute to the reduced rate of nocturnal hypoglycaemia that is observed clinically. Reasons for the difference in pharmacokinetic profile between Gla-100 and Gla-300 are not known, but may be due to factors inherent to the retarding principle of the insulin glargine molecule and a phenomenon of surface-dependent release.[@R4] [@R5] Gla-300 has a pH of approximately 4, at which it is completely soluble; however, once injected subcutaneously, the solution is neutralised and forms a precipitate allowing for the slow release of small amounts of insulin glargine. It has been suggested that the size (ie, surface area) of the subcutaneous deposit may determine the redissolution rate.[@R51]

The finding of a significantly lower rate of nocturnal hypoglycaemia associated with a basal insulin analogue compared with NPH is consistent with previous meta-analyses. For example, a meta-analysis of randomised clinical trials comparing long-acting basal insulin analogues (Gla-100 or detemir) with NPH showed that, among 10 studies reporting data for nocturnal hypoglycaemia, both analogues were associated with a reduced risk of nocturnal events, with an OR of 0.46 (95% CI 0.38 to 0.55) compared with NPH.[@R52] Similarly, in the pivotal Treat-to-Target study comparing Gla-100 to NPH, the risk reduction with Gla-100 ranged from 42% to 48% for different categories of nocturnal hypoglycaemic events.[@R26] A subsequent meta-analysis of individual patient data from 5 randomised clinical trials comparing Gla-100 to NPH, reported reductions of approximately 50% in nocturnal hypoglycaemia with Gla-100.[@R53] Given these data, along with patient-level data from the EDITION trials,[@R6] which when pooled[@R54] demonstrated a 31% lower relative difference in the annualised rate of nocturnal events over the 6-month study period for Gla-300 compared with Gla-100, the even more pronounced difference in the rate of nocturnal events between Gla-300 and NPH in this NMA is expected.

The finding of fewer nocturnal hypoglycaemic events with Gla-300 compared with premixed insulin in this NMA is in line with 'real-world' data from the Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy (CREDIT) study, an international observational study that provided insights on outcomes following insulin initiation in clinical practice.[@R55] In CREDIT study, propensity-matched groups were evaluated 1 year after initiating insulin treatment and showed that basal insulin was associated with significantly lower rates of nocturnal hypoglycaemia compared with premixed insulin. This also held true for propensity-matched analysis of basal plus mealtime insulin versus premixed insulin groups.

The substantially lower risk of nocturnal hypoglycaemia associated with Gla-300 is an important finding given the clinical burden associated with such events.[@R56] In a multination survey of 2108 patients with diabetes (types 1 and 2) who had recently experienced nocturnal hypoglycaemia, patients reported a negative impact on their sleep quality as well as their functioning, the day after a nocturnal hypoglycaemic event.[@R57] Nocturnal events were associated with increased self-monitoring of blood glucose, and approximately 15% of patients reported temporary reductions in insulin dose. An economic evaluation of these data found that nocturnal hypoglycaemic events were associated with lost work productivity and increased healthcare utilisation.[@R58] Utilisation costs were estimated to be higher among patients who injured themselves due to a trip or fall associated with their nocturnal hypoglycaemia episode (approximately \$2000 per person annually).

While the findings of this NMA are promising for Gla-300, several limitations are evident. The studies included in this NMA were of open-label design, which is inherently subject to bias; however, this type of methodology is typically used in trials comparing insulin therapies due to visible differences between insulin products and/or differences in injection devices. A potential issue is that there was no multiplicity adjustment, and given that there were multiple comparisons, it is possible that positive findings were due to chance. In addition, trial-level summary data may not have been adequately powered to detect differences between products---for example, while randomised controlled studies of Gla-100 versus Gla-300 and pooled patient level data from these studies have shown that Gla-300 is associated with a significantly lower rate of nocturnal hypoglycaemia, the trial-level data comparisons in this NMA did not achieve significance for this end point. Finally, a well-recognised limitation of any NMA is that, by design, these are not randomised comparisons; however, these data can aid the decision-making process until prospective randomised comparative clinical trial data become available.

Strengths of the current NMA include that it was conducted in accordance with established NICE guidelines and that the estimates reported are in line with those in previous meta-analyses of comparative basal insulin studies.[@R52] [@R53] [@R59] [@R60] NMA provides the capability of considering different pathways simultaneously rather than simple indirect pairwise comparison through multiple pathways. Another strength is the quality of studies included in the NMA (ie, the majority had discontinuation rates \<20%). The studies included were similar in design and, from a clinical standpoint, heterogeneity of the patient population was not considered an issue. Results of the NMA were internally consistent with what was reported in individual RCTs. Finally, extensive sensitivity analyses considering subsets of studies, different hypoglycaemia definitions and adjusting for trial-level characteristics, supported the robustness of the findings.

In conclusion, clinical trial findings and the results from this NMA suggest that Gla-300 in the treatment of T2DM is associated with a lower rate of nocturnal hypoglycaemia than treatment with premixed insulin and NPH, while demonstrating comparable glycaemic control versus all comparators. Change in body weight was significantly lower for Gla-300 versus premixed insulin, and comparable with other basal insulin. These NMA data, along with randomised clinical trial findings of reduced nocturnal hypoglycaemia and comparable clinical benefits for Gla-300 versus Gla-100, suggest that this new basal insulin represents an important advance in insulin treatment for patients with T2DM.
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